ClinicalTrials.gg
TerminatedNCT04447872Updated Nov 20, 2026

The LUTEAL Trial: Luteal Stimulation vs. Estrogen Priming Protocol

An interventional study of Timing of injectable gonadotropins in Infertility, Diminished Ovarian Reserve and IVF, sponsored by Northwell Health. Terminated at 1 site in United States. Open to female participants aged 20 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Northwell Health · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Lack of continued subject recruitment
Updated Nov 20, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 395 studies in Infertility with a site in United States — 62 open to participants now, 84 under way, 7 of them phase 3. Infertility · United States.

Enrollment
158th of 274
59 · median 84
Started
2020
with 19 others
No phase
168 of 395
24 open now
Registered
296th of 395
by date

Among the 395 studies in Infertility with a site in United States, this one is the 158th largest by enrollment of the 274 interventional ones that give a count, is one of 20 that started in 2020, is one of 168 with no phase, and was the 296th registered.

Infertility

2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

62 of the 395 studies in Infertility with a site in United States are open now. Recruiting first, the newest first:

57 more — sign in →

All 62 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 20 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 395 studies in Infertility with a site in United States, or all of them as a file.
02

Study summary

Ovarian reserve defines the quantity and quality of the ovarian primordial follicular pool. Diminished ovarian reserve (DOR) indicates a reduction in the quantity of ovarian follicular pool to less than expected for age. It is an important cause of infertility in many couples.

To date, there is no clear consensus in the literature on the definition of diminished ovarian reserve, and it is unclear whether low oocyte yield results from an abnormal atresia rate of the follicle pool, or from a lower follicle pool at birth or whether it can just occur as a normal variation in the population.

The ovarian response to controlled ovarian stimulation with gonadotropins (for example, for in vitro fertilization) is largely determined by the ovarian reserve, and there are numerous different ovarian stimulation protocols that are employed to try and increase the oocyte yield of a particular cycle. There is no consensus on which, if any, of these protocols are superior and preferred for patient with DOR.

Luteal gonadotropin stimulation is a protocol of controlled ovarian stimulation (COS) for use in assisted reproductive technologies (ART) that has emerged over the past decade as an acceptable alternative to the classic follicular gonadotropin stimulation.

The luteal estradiol patch protocol was introduced in 2005 in patients with poor response to controlled ovarian stimulation (COS) and to address the phenomenon of early follicle recruitment in patients with diminished ovarian reserve (DOR). Luteal gonadotropin stimulation can potentially achieve the same effect by initiating follicular recruitment for IVF prior to the body's own premature recruitment.

Our hypothesis is that the luteal stimulation protocol and estradiol priming protocol are equivalent with regard to the outcome of number of mature oocytes retrieved. Patients who will be undergoing controlled ovarian stimulation and who have a diagnosis of diminished ovarian reserve will be considered for this trial, and enrolled if meeting all inclusion and no exclusion criteria.

Read the detailed description

Patients who will be undergoing controlled ovarian stimulation and who have a diagnosis of diminished ovarian reserve will be considered for this trial, and enrolled if meeting all inclusion and no exclusion criteria. Patients will be randomized to one of two possible stimulation cycles as will be described.

Luteal Phase Ovarian Stimulation (LPOS)

Patients will present for an appointment on approximately day 15-18 of her menstrual cycle. If serum progesterone >3 ng/mL, and bHCG \< 5 mIU/mL, the patient will begin 450 IU of daily injectable gonadotropins: 150 IU of hMG (Menopur®, Ferring Pharmaceuticals) and 300 IU of recombinant FSH (rFSH) (Gonal F®,Serono; or Follitropin beta (Follistim®, Organo)). The specific rFSH chosen will be based on the individual patient's insurance coverage. The patient will perform daily injections during the course of her stimulation, and will also take oral Clomiphene citrate 100mg daily for the first five days of the stimulation. FSH dose will be titrated during the stimulation (per physician discretion) based on serum estradiol levels and ovarian response to a minimum of no gonadotropins and a maximum of 600 IU daily. She will present for follicular monitoring ultrasound and serum blood tests on stimulation day 3-4, 5-6, and 7-8-\~15. Gonadotropin releasing hormone (GnRH) antagonist (Ganirelix, Organon; and cetrorelix, Serono) will be started daily once either (1) serum estradiol level reaches > 400 pg/mL, lead follicle size > 13mm, or (2) on stimulation day 6. Once patient are ready for ovulation trigger as determine by physician, 5-10,000 units of human chorionic gonadotropin (Novarel®: Ferring Pharmaceuticals; or Pregnyl®: Schering-Plough) will be administered. A patient's trigger shot could be changed to include a GnRH agonist (i.e Luprolide acetate 40 IU) if deemed clinically necessary for ovarian hyperstimulation syndrome prevention. On the morning after hCG administration, patients' blood will be drawn and serum analyzed for hCG concentration to ensure adequate absorption (mean time 8-10 hours). Transvaginal oocyte retrieval will be performed 35 to 37 hours after hCG trigger. All metaphase II oocytes will be fertilized with intracytoplasmic sperm injection (ICSI) or IVF per patient request and laboratory protocol. Embryos will be cultured to the blastocyst stage and vitrified on day 5-7. If patient requests preimplantation genetic testing for aneuploidy (PGT-A), an embryo biopsy will be performed on day 5-7 of development prior to vitrification, and biopsy specimen will be sent to an outside laboratory for chromosome analysis.

Luteal Estradiol priming protocol (E2 prime)

Patients will present for an appointment on approximately day 18-21 of her menstrual cycle. If serum progesterone >3 ng/mL, and bHCG \< 5 mIU/mL, the patient will begin Estradiol patches (Vivelle Dot 0.1mg, Novartis Pharmaceuticals; or Climara, Bayer) and change them every other day. She will also take daily Gonadotropin releasing hormone (GnRH) antagonist (Ganirelix, Organon; and cetrorelix, Serono) for the following three days.

Patients will then present for a baseline appointment with onset of her menses. If serum progesterone \< 1.0 ng/mL, and bHCG \< 5 mIU/mL, on cycle day 2-3 the patient will stop her estrogen patches and start 450 IU of daily injectable gonadotropins: 150 IU of hMG (Menopur®, Ferring Pharmaceuticals) and 300 IU of recombinant FSH (rFSH) (Gonal F®,Serono; or Follitropin beta (Follistim®, Organo)). The specific rFSH chosen will be based on the individual patient's insurance coverage. Estrogen patch will be removed the day of starting gonadotropin injections. The patient will perform daily injections during the course of her stimulation, and will also take oral Clomiphene citrate 100mg daily for the first five days of the stimulation. FSH dose will be titrated during the stimulation (per physician discretion) based on serum estradiol levels and ovarian response to a minimum of no gonadotropins and a maximum of 600 IU daily. She will present for follicular monitoring ultrasound and serum blood tests on stimulation day 3-4, 5-6, and 7-8-\~15. Gonadotropin releasing hormone (GnRH) antagonist (Ganirelix, Organon; and cetrorelix, Serono) will be started daily once either (1) serum estradiol level reaches > 400 pg/mL, lead follicle size > 13mm, or (2) on stimulation day 6. Once patient are ready for ovulation trigger as determine by physician, 5-10,000 units of human chorionic gonadotropin (Novarel®: Ferring Pharmaceuticals; or Pregnyl®: Schering-Plough) will be administered. A patient's trigger shot could be changed to include a GnRH agonist (i.e Luprolide acetate 40 IU) if deemed clinically necessary for ovarian hyperstimulation syndrome prevention. On the morning after hCG administration, patients' blood will be drawn and serum analyzed for hCG concentration to ensure adequate absorption (mean time 8-10 hours). Transvaginal oocyte retrieval will be performed 35 to 37 hours after hCG trigger. All metaphase II oocytes will be fertilized with intracytoplasmic sperm injection (ICSI) or IVF per patient request and laboratory protocol. Embryos will be cultured to the blastocyst stage and vitrified on day 5-7. If patient requests preimplantation genetic testing for aneuploidy (PGT-A), an embryo biopsy will be performed on day 5-7 of development prior to vitrification, and biopsy specimen will be sent to an outside laboratory for chromosomal analysis.

Outcomes between the two stimulation protocols will be compared.

03

Conditions studied

  • Infertility
  • Diminished Ovarian Reserve
  • IVF

Browse trials for

Keywords

  • IVF
  • In Vitro Fertilization
  • DOR
  • Diminished Ovarian Reserve
  • Controlled ovarian stimulation
04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated form
  2. Stated willingness to comply with all study procedures and availability for the duration of the study
  3. Female aged 20 - 45
  4. Regular menstrual cycles between 21 and 40 days
  5. Presence of both ovaries
  6. Meets criteria for DOR by the recent ASRM/ACOG Committee Opinion

    1. antimüllerian hormone (AMH) value less than 1 ng/mL
    2. antral follicle count less than 5-7 and
    3. follicle-stimulating hormone (FSH) greater than 10 IU/L or
    4. a history of poor response to in vitro fertilization stimulation (fewer than four oocytes at time of egg retrieval).

Exclusion criteria

Exclusion Criteria:

  1. Oocyte donation cycle
  2. Oocyte freezing cycle
  3. Current ovarian cyst > 3cm
  4. Anovulatory or oligo-ovulatory (\<6 ovulation per year)
  5. Previous oophorectomy
  6. Exposure to cytotoxic or pelvic irradiation
  7. Planned aromatase inhibitor usage during current ovarian stimulation
  8. Sensitizing or ovarian stimulating therapy in the past one month

    Additional to this study re, as follows (because such patients cannot receive an estrogen patch):

  9. Undiagnosed abnormal genital bleeding
  10. Known, suspected, or history of breast cancer
  11. Known or suspected estrogen-dependent neoplasia
  12. Active DVT, PE, or a history of these conditions
  13. Active arterial thromboembolic disease (for example, stroke and MI), or a history of these conditions
  14. Known anaphylactic reaction or angioedema with estradiol patches
  15. Known liver impairment or disease
  16. Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
59 participants (actual)

Study arms

  • Active comparator
    Luteal phase ovarian stimulation (LPOS)

    Patients will present in the luteal phase, and will begin 150 IU hMG and 300 IU recombinant FSH daily, as well as oral Clomiphene citrate 100mg daily for the first five days of the stimulation. FSH can then be titrated per patient response. Gonadotropin releasing hormone antagonist (Ganirelix, Organon; and cetrorelix, Serono) will be started per criteria. Once patients are ready for ovulation trigger, 5-10,000 units of human chorionic gonadotropin, +/- GnRH agonist (i.e Luprolide acetate 40 IU), will be administered. All metaphase II oocytes obtained by oocyte retrieval will be fertilized with intracytoplasmic sperm injection (ICSI) or IVF. Embryos will be cultured to the blastocyst stage and vitrified on day 5-7 with or without embryo biopsy for genetic analysis.

    Procedure: Timing of injectable gonadotropins

  • Active comparator
    Luteal estradiol priming protocol

    In the luteal phase, the patient will begin Estradiol patches 0.1mg QOD. She will also take daily Gonadotropin releasing hormone (GnRH) antagonist (Ganirelix, Organon; and cetrorelix, Serono) for three days. With menses, she will begin 150 IU hMG, 300 IU recombinant FSH daily, and oral Clomiphene citrate 100mg qd (for five days). FSH can be titrated per patient response. GnRH antagonist will be started per criteria. 5-10,000 units of human chorionic gonadotropin, +/- GnRH agonist (i.e Luprolide acetate 40 IU) will be administered for ovulation trigger. All metaphase II oocytes obtained by oocyte retrieval will be fertilized with intracytoplasmic sperm injection (ICSI) or IVF. Embryos will be cultured to the blastocyst stage and vitrified on day 5-7 with or without embryo biopsy for genetic analysis.

    Procedure: Timing of injectable gonadotropins

Interventions

  • ProcedureTiming of injectable gonadotropins

    Gonadotropins will with be started in the luteal phase or in follicular phase (preceded by Estradiol patches)

06

What researchers measure

Primary outcomes

  1. Number of mature (Metaphase II) oocytes retrieved

    Mature oocytes, capable of being fertilized in vitro

    Time frame: First day after oocyte retrieval

Secondary outcomes

  1. Number of oocytes cumulus complexes retrieved

    Total oocytes from oocyte retrieval

    Time frame: First day after oocyte retrieval

  2. Oocyte fertilization rate

    Rate of oocytes that develop two pronuclei

    Time frame: First day after oocyte retrieval

  3. Blastocyst development rate

    Rate of embryos that develop to the blastocyst stage

    Time frame: Day 5-7 following oocyte retrieval

  4. Cycle cancellation rate

    Rate of cycle cancellation prior to oocyte retrieval

    Time frame: Within two weeks of cycle start

  5. Total FSH dosage (IU) used

    Total dosage of injected gonadotropins during ovarian stimulation

    Time frame: From the first day of injections, through the day of oocyte retrieval

  6. Duration of stimulation (days)

    How many days from first injection until trigger shot injection

    Time frame: From the first day of injections, through the day of oocyte retrieval

Other outcomes

  1. Embryo ploidy status

    If patient undergoes preimplantation for genetic testing of aneuploidy (PGT-A), we will compare the rate of euploid embryos between the groups

    Time frame: When biopsy results return, usually within four weeks after oocyte retrieval

  2. Implantation rate

    Rate of successful embryo implantation if undergoes embryo transfer

    Time frame: Two weeks post embryo transfer

  3. Clinical pregnancy rate

    Rate of successful clinical intrauterine pregnancy if undergoes embryo transfer

    Time frame: Five to seven weeks post embryo transfer

  4. Live birth rate

    Rate of live birth if undergoes embryo transfer

    Time frame: 40 weeks post embryo transfer

07

Study locations

1 site
  • Northwell Fertility
    Manhasset, New York 11030, United States
08

References and documents

Publications

  • Lin LT, Vitale SG, Chen SN, Wen ZH, Tsai HW, Chern CU, Tsui KH. Luteal Phase Ovarian Stimulation May Improve Oocyte Retrieval and Oocyte Quality in Poor Ovarian Responders Undergoing In Vitro Fertilization: Preliminary Results from a Single-Center Prospective Pilot Study. Adv Ther. 2018 Jun;35(6):847-856. doi: 10.1007/s12325-018-0713-1. Epub 2018 Jun 4. PubMed 29869107 ↗
  • Zhang W, Wang M, Wang S, Bao H, Qu Q, Zhang N, Hao C. Luteal phase ovarian stimulation for poor ovarian responders. JBRA Assist Reprod. 2018 Sep 1;22(3):193-198. doi: 10.5935/1518-0557.20180045. PubMed 29931967 ↗
  • Wei LH, Ma WH, Tang N, Wei JH. Luteal-phase ovarian stimulation is a feasible method for poor ovarian responders undergoing in vitro fertilization/intracytoplasmic sperm injection-embryo transfer treatment compared to a GnRH antagonist protocol: A retrospective study. Taiwan J Obstet Gynecol. 2016 Feb;55(1):50-4. doi: 10.1016/j.tjog.2015.07.001. PubMed 26927248 ↗
  • Wu Y, Zhao FC, Sun Y, Liu PS. Luteal-phase protocol in poor ovarian response: a comparative study with an antagonist protocol. J Int Med Res. 2017 Dec;45(6):1731-1738. doi: 10.1177/0300060516669898. Epub 2017 Jan 16. PubMed 28661216 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Sep 2020 to primary completion in Dec 2024, 51 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Jun 2025 → Dec 2024 and completion Jun 2025 → Dec 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2020
First posted
Jun 25, 2020
StartActual
Sep 15, 2020
Primary completionActual
Dec 20, 2024was Jun 2025
CompletionActual
Dec 20, 2024was Jun 2025
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated Lack of continued subject recruitment
changed Nov 20, 2026
Primary completion
Jun 2025→Dec 20, 2024 (actual)
Nov 20, 2026
Study completion
Jun 2025→Dec 20, 2024 (actual)
Nov 20, 2026
Enrollment
142 (estimated)→59 (actual)
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Recruiting→Terminated
    Why stopped Lack of continued subject recruitment
    Primary completion Jun 2025→Dec 20, 2024 (now actual)
    Study completion Jun 2025→Dec 20, 2024 (now actual)
    Enrollment 142 (estimated)→59 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04447872
Lead sponsor
Northwell Health
Responsible party
Mary Rausch, MD (Assistant Professor, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Northwell Health) — Principal investigator
First posted
Jun 25, 2020
Start date
Sep 15, 2020
Primary completion
Dec 20, 2024
Completion
Dec 20, 2024
Last update
Nov 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion